- Immune thrombocytopenic purpura worsened by COVID-19
-
Kim CS, Choi DR, Lee JH
- KMID: 2524099
- Blood Res.
- 2021 Dec;56(4):347-349.
- doi: 10.5045/br.2021.2021147
-
- CITED
-
- Close
- SHARE
-
- Close
- Shared molecular basis, diagnosis, and co-inheritance of alpha and beta thalassemia
-
Khatri G, Sahito AM, Ansari SA
- KMID: 2524093
- Blood Res.
- 2021 Dec;56(4):332-333.
- doi: 10.5045/br.2021.2021128
-
- CITED
-
- Close
- SHARE
-
- Close
- Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
-
Cencini E, Fabbri A, Raspadori D, Gozzetti A, Bocchia M
- KMID: 2524094
- Blood Res.
- 2021 Dec;56(4):333-334.
- doi: 10.5045/br.2021.2020322
-
- CITED
-
- Close
- SHARE
-
- Close
- Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy
-
Polprasert C, Wudhikarn K, Rojnuckarin P
- KMID: 2524068
- Blood Res.
- 2021 Dec;56(4):209-211.
- doi: 10.5045/br.2021.2021123
-
- CITED
-
- Close
- SHARE
-
- Close
- Subclinical thrombotic thrombocytopenic purpura after vaccination with ChAdOx1 nCoV-19
-
Jang HR, Lim KH
- KMID: 2524069
- Blood Res.
- 2021 Dec;56(4):212-214.
- doi: 10.5045/br.2021.2021140
-
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
-
Lee JW, Yoo JW, Kim S, Jang PS, Chung NG, Cho B
- KMID: 2524097
- Blood Res.
- 2021 Dec;56(4):342-345.
- doi: 10.5045/br.2021.2021104
-
- CITED
-
- Close
- SHARE
-
- Close
- A look inside the body of a BCR-ABL1−like acute lymphoblastic leukemia patient: the first case report highlighting the continued relevance of autopsy practice
-
Rastogi P, Bhatia P, Sreedharanunni S, Lad D
- KMID: 2524095
- Blood Res.
- 2021 Dec;56(4):335-339.
- doi: 10.5045/br.2021.2020231
-
- CITED
-
- Close
- SHARE
-
- Close
- A case of e1a2 (minor, P190) BCR-ABL1-positive chronic myeloid leukemia in Korea
-
Choi YJ, Heo JY, Yoo J
- KMID: 2524098
- Blood Res.
- 2021 Dec;56(4):345-347.
- doi: 10.5045/br.2021.2020331
-
- CITED
-
- Close
- SHARE
-
- Close
- Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma
-
Yi JH, Jang JH, Jung CW
- KMID: 2524100
- Blood Res.
- 2021 Dec;56(4):349-353.
- doi: 10.5045/br.2021.2021197
-
- CITED
-
- Close
- SHARE
-
- Close
- Therapy-related acute myeloid leukemia in a patient with B-cell acute lymphoblastic leukemia
-
Gajendra S, Gore AR, Jha B, Sood N, Bhargava M
- KMID: 2524096
- Blood Res.
- 2021 Dec;56(4):339-342.
- doi: 10.5045/br.2021.2021093
-
- CITED
-
- Close
- SHARE
-
- Close
- Effects and treatment applications of polymeric nanoparticles on improving plateletsÊ storage time: a review of the literature from 2010 to 2020
-
Mehrizi TZ, Kafiabad SA, Eshghi P
- KMID: 2524071
- Blood Res.
- 2021 Dec;56(4):215-228.
- doi: 10.5045/br.2021.2021094
Maintaining the quality of platelet products and increasing their storage time are priorities for treatment applications. The formation of platelet storage lesions that limit the storage period and preservation temperature,... -
- CITED
-
- Close
- SHARE
-
- Close
- Blood management strategies in congenital Glanzmann thrombasthenia at a hematology referral center
-
Kasinathan G, Sathar J
- KMID: 2524091
- Blood Res.
- 2021 Dec;56(4):315-321.
- doi: 10.5045/br.2021.2021165
Background Glanzmann thrombasthenia is associated with abnormalities in the glycoprotein IIb/IIIa receptor. This study, conducted at Ampang Hospital, Malaysia, aimed to assess outcomes of blood management strategies for Glanzmann thrombasthenia. Methods Ten patients... -
- CITED
-
- Close
- SHARE
-
- Close
- A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
-
Nekoukar Z, Moghimi M, Salehifar E
- KMID: 2524073
- Blood Res.
- 2021 Dec;56(4):229-242.
- doi: 10.5045/br.2021.2021117
Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known... -
- CITED
-
- Close
- SHARE
-
- Close
- Mutation analysis and characterisation of F9 gene in haemophilia- B population of India
-
Kulkarni S, Hegde R, Hegde S, Kulkarni SS, Hanagvadi S, Das KK, Kolagi S, Gai PB, Bulagouda R
- KMID: 2524077
- Blood Res.
- 2021 Dec;56(4):252-258.
- doi: 10.5045/br.2021.2021016
Background Hemophilia B (HB) is an X-linked bleeding disorder resulting from coagulation factor IX defects. Over 3,000 pathogenic, HB-associated mutations in the F9 gene have been identified. We aimed to investigate... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-life ruxolitinib experience in intermediate-risk myelofibrosis
-
Arikan F, Toptas T, Atagunduz IK, Ercan T, Oruc O, Yilmaz F, Tuglular T
- KMID: 2524092
- Blood Res.
- 2021 Dec;56(4):322-331.
- doi: 10.5045/br.2021.2021101
Background In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated. Methods The median... -
- CITED
-
- Close
- SHARE
-
- Close
- The demographic, clinical, and medical manifestations of pulmonary thromboembolism development in COVID-19
-
Sadeghi S, Nasirian M, Keivany E, Nasri P, Mirenayat MS
- KMID: 2524089
- Blood Res.
- 2021 Dec;56(4):293-300.
- doi: 10.5045/br.2021.2021131
Background Since the emergence of coronavirus disease 2019 (COVID-19), various clinical manifestations ranging from asymptomatic to severe, life-threatening courses have been presented. It is well known that COVID-19 patients are at... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical features and outcomes of JAK2V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2V617F allele burden
-
Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH
- KMID: 2524084
- Blood Res.
- 2021 Dec;56(4):259-265.
- doi: 10.5045/br.2021.2021089
Background JAK2mutation status is a well-known risk factor for thrombosis in patients with myeloproliferative neoplasms. However, the clinical usefulness of JAK2V617F allele burden is under investigation. Methods We retrospectively evaluated the impact of... -
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
-
Hur JY, Yoon SE, Kim D, Choi Jo, Min JH, Kim BJ, Kim JS, Lee JE, Choi JY, Jeon ES, Kim SJ, Kim K
- KMID: 2524086
- Blood Res.
- 2021 Dec;56(4):266-278.
- doi: 10.5045/br.2021.2021121
Background Treatment protocols for light chain (AL) amyloidosis have been derived from myeloma treatment. Bortezomib is a key drug used for the treatment of myeloma and AL amyloidosis. We retrospectively investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999‒2018
-
Park WJ, Park JH, Cho S, Shin MG
- KMID: 2524090
- Blood Res.
- 2021 Dec;56(4):301-314.
- doi: 10.5045/br.2021.2021187
Background In this study, we presented the national cancer statistics on the incidence of hematologic malignancies in the Republic of Korea (ROK) over a period of 20 years, from 1999 to... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan
-
Ma’koseh M, Amarin R, Tamimi F, Sharaf B, Abufara A, Shahin O, Manassra MKM, Halahleh K
- KMID: 2524087
- Blood Res.
- 2021 Dec;56(4):279-284.
- doi: 10.5045/br.2021.2021116
Background The treatment of adult Burkitt lymphoma with pediatric-based chemotherapy protocols usually results in high cure rates, although with significant toxicity. We report our experience with the Cancer and Leukemia Group... -
- CITED
-
- Close
- SHARE
-
- Close
